Savara Stock (NASDAQ:SVRA)
Previous Close
$2.70
52W Range
$1.89 - $4.70
50D Avg
$2.38
200D Avg
$2.86
Market Cap
$445.92M
Avg Vol (3M)
$1.56M
Beta
0.40
Div Yield
-
SVRA Company Profile
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.